Search results for "oligonucleotides"

Article Future Downstream Process Development Solutions for Advanced Therapies
downstream  Click here to view more Industry Leader Q&As >>  Peter Guterstam, PhD, Product Manager of Next Generation Resins & Technologies at Cytiva, provides insight into solutions for ad…

Article Gene Therapies Push Viral Vector Production
“Apart from plasmids there are liposomes, lipoplexes, polyplexes, and oligonucleotides [that can be used] as non-viral modes of gene delivery.” Vicaire also notes that using non-viral vehicles …

Article Biopharma Manufacturers Respond to Ebola Crisis
Demand for new therapies and vaccines spotlights production challenges. Oct 1, 2014 By: Jill Wechsler BioPharm International Volume 27, Issue 10, pp. 8-9 The development of new tr…

Article Q&As with Industry Leaders
Discovering the unknown: How does in silico process development change PD scientists’ work? Jeanne Linke Northrop, BioPharm International Nora Ketterer, Manager, Modeling Services…

Article Quality by Design—Bridging the Gap between Concept and Implementation
The drive to embed quality-by-design (QbD) principles into the pharmaceutical regulatory framework of the European Union has reached a key point 10 years after the European Medicines Agency (EMA) firs…

Previous Page